Complement: Help or hindrance?

Blood

Volumn 114, Issue 27, 2009, Pages 5567-5668

  Beers, Stephen A ^a   Cragg, Mark S ^a   Glennie, Martin J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; COMPLEMENT ACTIVATION; IMMUNOTHERAPY; LETTER; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; NOTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMPLEMENT C3; DISEASE MODELS, ANIMAL; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE;

EID: 76249096572     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-249466     Document Type: Letter

References (10)

1. Wang S-Y, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009;114(26):5322-5330.
2. Cragg MS, Bayne MB, Tutt AL, et al.Anew anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood. 2004;104(8):2540- 2542.
3. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91(2):176-183.
4. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005;174(7):4389-4399.
5. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205-1213.
6. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. Prepublished on September 22, 2009, as doi 10.3324/haematol. 2008.001628.
7. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
8. van Ojik HH, Bevaart L, Dahle CE, et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 2003;63(17):5595-5600.
9. Younger JG, Sasaki N, Delgado J, et al. Systemic and lung physiological changes in rats after intravascular activation of complement. J Appl Physiol. 2001;90(6):2289-2295.
10. Franki SN, Steward KK, Betting DJ, Kafi K, Yamada RE, Timmerman JM. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood. 2008;111(3):1504- 1511.